We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Reckitt Benckiser Group Plc | LSE:RB. | London | Ordinary Share | GB00B24CGK77 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6,498.00 | 6,502.00 | 6,506.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
05/7/2011 17:20 | From FT.com/Alphaville - Neil Hume Depending on which publication you read this morning, Reckitt was either going to be acquired by either Proctor & Gamble or Unilever for anything between £40-£50 a share (curiously round numbers aren't they? Ed.) Now, one should never say never, but a bid from either company looks to be a long shot, says the sector's top-rated analyst, Andrew D Wood of Sanford Bernstein: Given the sustained speculation of a potential bid for RB, I thought it might be worthwhile re-distributing this report we published in April. It primarily looks at potential anti-trust issues for the usual suspects (P&G, Unilever, Colgate), but we also make comments on the potential for acquisition as well. In particular I would highlight the following extract from the report: Our [anti-trust] analysis is not definitive, and clearly could be addressed by joint bids or bids where the bidder is prepared to accept significant remedies in order to get the deal done...but it does suggest that any hope that RB could be subject to aggressive pursuit from P&G are slim. Unilever could probably pursue RB, but we believe that the business is still in turnaround "show me" mode under a fairly new CEO, and an aggressive pursuit of a £29bn (32bn, $47bn) acquisition, assuming an acquisition price of £40, would not get the support of the board or investors. RB is also probably too big for Colgate to swallow...but a merger of equals could be considered, and anti-trust issues would not preclude the deal. Hmm, a merger with Colgate. That has also been rumoured and it's said to be the real reason behind Bart Becht's surprise departure from Reckitt. He was pushing for a transformational merger and the board blocked him. And it's certainly a goer. Colgate would have only minor issues...mostly limited to surface care from a category perspective and Greece and Australia from a country perspective. We estimate that only 3% of RB's sales in the EU would be at high risk or risk of anti-trust issues, and only 6% of sales globally. Once again, anti-trust remedies would probably not preclude a deal. As opposed to bid from P&G... P&G would find it difficult to get a deal done. We see significant anti-trust issues in a number of important categories (Surface Care, Auto Dishwash, Laundry Aids and Depilatories) in a number of countries (US, Canada, most of the EU). We estimate that 44% of RB's sales in the EU would be at high risk or risk of anti-trust issues, and 31% of sales globally. We conclude that required anti-trust remedies would probably block a deal. Wood reckons the real reason Reckitt has rallied today is a growing appreciation of its fundamentals - steadily improving core markets and sales growth as 2011 progresses , good news and more bullish guidance on the Pharma business (especially the transfer from Suboxone Tablets to Film) and strong success with the integration of Durex condom maker SSL. | batman9 | |
05/7/2011 16:20 | Reckitt Benckiser, the maker of Cillit Bang and Dettol, gave support to the market following speculation that Unilever and Proctor & Gamble were circling the company for a takeover bid. Shares were ahead 61p at 3549p. Read more: | batman9 | |
05/7/2011 10:46 | From the Guardian Reckitt Benckiser, the maker of Cillit Bang and Dettol, was the day's speculative tale, up 35p to £34.88 on renewed talk of a possible offer for the company at around £50 a share. The supposed predator was Unilever, 25p higher at £20.37, with traders suggesting the Anglo-Dutch group could sell on any unwanted Reckitt brands to US rival Colgate-Palmolive. The timing would be interesting - Reckitt's long standing chief executive Bart Becht is due to step down in September. | batman9 | |
05/7/2011 09:16 | Household goods and healthcare products conglomerate Reckitt Benckiser continued to attract buyers, adding 52p at 3,540p, as bid rumours persisted, with Unilever in the frame. Unilever shares dipped 2p at 2,035p in response. | batman9 | |
24/6/2011 14:25 | Broker upgrade-BUY-target 4500p | nellie1973 | |
20/6/2011 08:25 | Some good news this am, especially as it is co-inciding with Pfzier's loss of the Viagra patent :) TIDMFUM RNS Number : 6992I Futura Medical PLC 20 June 2011 For immediate release 20 June 2011 Futura Medical plc ("Futura" or "the Company") CSD500 CE mark certification Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce it has been informed that the relevant Notified Body is satisfied that all outstanding points in the regulatory dossier for CSD500 have been resolved and has been recommended to their Review Panel for approval. The Panel'sapproval process typically takes a month and is already underway. A further statement will be made in the coming weeks regarding the issueof the CE mark certificate. The CE mark certificate will enable CSD500 to be marketed and sold within 29 European territories and a number of other non-European territories that recognise the CE mark process. Reckitt Benckiser plc, makers of the Durex(R) branded condom have exclusive global rights to CSD500. For any further information please contact: Futura Medical plc James Barder, Chief Executive Tel: +44 (0) 1483 685 670 mail to: james.barder@futuram Nomura Code Securities Limited Phil Walker / Giles Balleny Tel:+44 (0)20 7776 1200 For media enquiries please contact: Buchanan Communications Mark Court / Jessica Fontaine Tel: +44 (0) 20 7466 5000 Notes to Editors Futura Medical plc Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups. Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.co This information is provided by RNS The company news service from the London Stock Exchange END | sportbilly1976 | |
20/4/2011 21:09 | A solid set of numbers, beat expectations on all metrics but most importantly margins were solid! This environment is all about pricing power and with a PE of 12.5 for next year against 14x for the market, this quality blue chip has yet to be re-rated. See you at 3600 very soon! | icf absolute | |
20/4/2011 12:27 | Great results !!! as always ! | soho2 | |
14/4/2011 14:57 | it was this price in October 2009... | deanroberthunt | |
14/4/2011 13:30 | With Bart and Colin both gone I think you might be right ICF, they were the staunch separatists, the rest are pretty much 'yes' men | dabaldek abbas | |
14/4/2011 13:23 | good op to get into a great co .. in my view ....... also Reckitt Benckiser's share price took a beating Thursday after the group announced the retirement of chief executive officer Bart Becht. Japanese broker Nomura says that while this isn't ideal, "we stay the course" and keeps its positive stance on the household products group. "We are not surprised by the share price reaction to the announcement...given [Becht's] personal association with the success of the company over the past 10 years," said the broker. Nomura suggests that the market was expecting him to stay in the role for some time yet, and will question the succession planning and timing following the departure of the long-term serving and well-regarded chief financial officer Colin Day announced in October. However, the broker says it is convinced that there is an underappreciated growth story in Developing Markets, potential to develop the Health & Personal Care franchise, and valuation upside to Suboxone. A 'buy' rating and 3,800p target price are maintained. --- | dawntrader | |
14/4/2011 13:00 | let's wait for the conference call at 16.00...we should see some upside shortly after...! | soho2 | |
14/4/2011 11:40 | Wait for the takeover from Colgate or Procter & Gamble due to these changes... | icf absolute | |
14/4/2011 10:43 | LOOKS LIKE A POSSIBLE CLASSIC W-FORMATION AT JUST OVER 3000P IMVHO | deanroberthunt | |
14/4/2011 09:31 | I agree its overdone and a fantastic buy at this price, strong support a little further down from here but I'm not waiting, in at a shade under 3100 | tweeeek | |
14/4/2011 09:15 | retirement of Chairman ????????????...just bought some more as this seems way overdone ! | soho2 | |
14/4/2011 08:23 | 2nd on the worst performer chart today?????? | soho2 | |
25/3/2011 17:08 | From a Lunchtime Bulletin: Reckitt Benckiser is wanted after Bank of America Merrill Lynch upgraded the stock of the Cillit Bang maker to "buy" from "neutral", | deanforester | |
25/3/2011 14:33 | The best blue chip at the midpoint was consumer products conglomerate Reckitt Benckiser, up 94p at 3,158p as it launched a new corporate campaign to raise its profile, also boosted by recent asset sales and a broker upgrade. | batman9 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions